---
title: "SKB Biopharma Gets China Nod for Marketing of Cancer Drug"
date: "2025-02-07 18:21:16"
summary: "Sichuan Kelun-Biotech Biopharmaceutical  obtained marketing authorization for its Cetuximab N01 injection from China's National Medical Products Administration, a Friday bourse filing said. The drug is used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of rat sarcoma virus wild-type metastatic colorectal cancer, according to the biopharmaceutical company."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Sichuan Kelun-Biotech Biopharmaceutical obtained marketing authorization for its Cetuximab N01 injection from China's National Medical Products Administration, a Friday bourse filing said.

The drug is used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of rat sarcoma virus wild-type metastatic colorectal cancer, according to the biopharmaceutical company.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250207:G2465091:0/)
